- Policy
- Government “Concerned of COVID-19 vaccine monopolization”
- by Lee, Hye-Kyung Jul 27, 2020 09:41am
- The South Korean government says it is closely following up with international sources to timely access the COVID-19 treatment and vaccine. At a regular briefing on July 23, Kwon Jun-wook, a deputy director of the Central Disease Control Headquarters, said “The disease control authority is paying a close attention to the global cases of
- Policy
- Betmiga’s price is temporarily on hold due to lawsuits
- by Kim, Jung-Ju Jul 27, 2020 09:41am
- Betmiga products by Astellas Korea, which are at risk of dropping more than 30%, are temporarily on hold due to lawsuits filed by Astellas. The court decided to keep the price before the adjustment for the time being until the ruling of Betmiga trial is over as requested by the company. The Seoul Administrative Court decided to extend
- Policy
- Lipiodol's suspension of price cuts has been extended
- by Kim, Jung-Ju Jul 27, 2020 09:41am
- The court decided to extend the suspension of drug price cuts against Guerbet Korea's Lipiodol Ultra Liquid (Iodized oil, 12.8g/10mL). The court set the suspension period to 30 days from the date of the sentence of judgment in preparation for prolonged litigation. Seoul Administrative Court decided to suspend execution of a decision re
- Policy
- Janssen launches clinical trial of Lazertinib-Amivantamab
- by Lee, Tak-Sun Jul 27, 2020 06:27am
- Janssen is conducting a clinical trial of Lazertinib for non-small cell lung cancer treatment with Amivantamab (JNJ-61186372). In 2018, Yuhan had transferred its technology of Lazertinib, a third-generation EGFR targeted anticancer drug to Janssen, to a total of &8361;1.4 trillion. The MFDS approved IND for clinical trial for Phase Ib of
- Policy
- No serious adverse effects for Duvie have been reported
- by Lee, Tak-Sun Jul 24, 2020 01:22pm
- After 6 years of post-marketing investigation of Duvie (Lobeglitazone sulfate), a new diabetes drug developed by Chong Kun Dang, serious adverse effects that cannot rule out a causal relationship with the drug has not been reported. The results of this PMS are positive because Thiazolidinediones (TZD) drugs had issue of side effects.
- Policy
- Drug purchase per Korean is OECD average 1.3 times higher
- by Kim, Jung-Ju Jul 24, 2020 06:24am
- It was found that the sales of medicines per capita in Korea amounted to USD 643 US PPP. This is 1.3 times more than the OECD 49 PPP average among OECD member countries. Antidepressants are about one-third of the average in member countries, but antibiotics are still high, with 1.6 times more. The MOHW (Minister Park Neung-Hoo) analyzed the l
- Policy
- SK Bioscience participates in supply of COVID-19 vaccine
- by Kim, Jung-Ju Jul 24, 2020 06:23am
- A domestic pharmaceutical bio company has been recognized for its production technology and has joined the world development leader multinational companies and the global production supply chain of COVID-19 vaccine. The government is trying to supply domestically some of the vaccines produced in Korea. The MOHW (Minister Park Neunghoo), t
- Policy
- Quadrivalent flu vaccines by GC and SK Bio get lot release
- by Lee, Tak-Sun Jul 23, 2020 06:11am
- Korea’s top influenza vaccine manufacturers GC Pharma and SK Bioscience have passed the government’s lot release side-by-side for their quadrivalent vaccines. Korea’s Ministry of Food and Drug Safety (MFDS) explained the approval was about a couple of weeks earlier than previous years, as the seasonal influenza could spread with COVID
- Policy
- HIRA says antibiotic prescription in flu down by 0.12%
- by Lee, Hye-Kyung Jul 22, 2020 06:16am
- [A look into Drug Reimbursement Evaluation Report 2019] Last year’s antibiotic prescription rate on acute upper respiratory tract infection fell by 0.21 percent from the previous year and was recorded at 38.30 percent. The number of drug item per prescription also climbed down by 0.05 item from 3.72 items in 2018 to 3.67 items in 2019
- Policy
- Chong Kun Dang generic to open Atozet generic market
- by Lee, Tak-Sun Jul 21, 2020 06:10am
- As Atozet’s post-marketing surveillance (PMS) expiration is approaching in next year, Chong Kun Dang is closely eyeing on the follow-on drug market. While many of Atozet (atorvastatin plus ezetimibe) generic makers are currently developing evidences like bioequivalence test to seek approval after Jan. 22 next year when the original’s P
